17 results about "Echinococcosis" patented technology

The invention discloses an SaRNA vaccine for echinococcosis as well as a preparation method and application of the SaRNA vaccine. The preparation method of the SaRNA vaccine comprises the following steps: carrying out codon optimization on a modified target antigen protein through a genetic engineering technology, then assembling the modified target antigen protein with a self-replicating protein sequence, 5 'UTR, 3' UTR and Poly (A) tail, carrying out gene synthesis, then cloning the synthesized gene into a plasmid, and carrying out purification to obtain the SaRNA vaccine. The preparation method comprises the following steps: constructing recombinant plasmids, sequentially carrying out plasmid linearization, in-vitro transcription and purification on the constructed recombinant plasmids to prepare SaRNA molecules, and finally wrapping the SaRNA molecules in lipid nanoparticles to form the SaRNA vaccine for the echinococcosis. Experiments prove that the SaRNA vaccine can activate humoral immunity and cellular immunity of mice at the same time, high-level EG95 specific antibodies and cytokines can be generated through low-dose immunity, and the SaRNA vaccine has wide application prospects in the aspect of preventing and / or treating the echinococcosis.

The invention relates to a vaccine for preventing and treating sheep echinococcosis infection and a preparation method thereof.The preparation method comprises the steps that echinococcosis Eg95 full-length gene antigen epitopes are screened through bioinformatics software, screened fragments with high antigenicity are optimized and then subjected to double-copy connection through a flexible linker, His tag sequences are added to the two ends of a tandem sequence, the sequence is as shown in SEQ ID NO.2, and the vaccine for preventing and treating sheep echinococcosis infection is obtained; and the pEE12.4-double Eg95 plasmid is connected with a CHO eukaryotic cell expression vector, so that the pEE12.4-double Eg95 plasmid is obtained. The plasmid is integrated into a CHO eukaryotic cell expression system, the expression quantity of the purified Eg95 protein reaches 10g / L, and a stable and high-yield veterinary vaccine is provided for large-scale production.

The invention discloses an echinococcosis mRNA (messenger Ribonucleic Acid) vaccine as well as a preparation method and application thereof. The preparation method of the mRNA vaccine for the echinococcosis comprises the following steps: carrying out codon optimization on a modified target antigen protein, then assembling the modified target antigen protein with 5 'UTR, 3' UTR and Poly (A) tail, carrying out gene synthesis, then cloning the synthesized gene into a pUC57 plasmid, and sequentially carrying out plasmid linearization, in-vitro transcription and purification on the constructed recombinant plasmid to prepare an mRNA molecule, thereby obtaining the mRNA vaccine for the echinococcosis. Finally, mRNA molecules are wrapped in lipid nanoparticles through a microfluidic method to form the mRNA vaccine for the echinococcosis, and immune effect evaluation is carried out on the mRNA vaccine for the echinococcosis. Experiments prove that the prepared mRNA vaccine for the echinococcosis can activate humoral immunity and cellular immunity of mice at the same time, can provide an effective protection effect for the mice attacking insects, and has a wide application prospect in the aspect of preventing and / or treating the echinococcosis.

The invention discloses an EmAGO2 truncated recombinant protein, an echinococcosis multilocularis indirect ELISA (enzyme-linked immuno sorbent assay) diagnostic kit based on the truncated recombinant protein and a use method of the kit. The method comprises the following steps: designing a specific primer by selecting a sequence of 1-738bp at the N end of an Em-AGO2 gene, carrying out PCR (Polymerase Chain Reaction) amplification by taking reverse transcription echinococcosis multilocularis DNA (Deoxyribonucleic Acid) as a template, connecting an amplification product with a pCE2-TA / Blunt vector, and then transforming into a competent cell for culturing, so as to obtain a pCE2-T-EmAGO2 plasmid; respectively carrying out double enzyme digestion on the plasmid and an expression vector pET-28a (+), and connecting enzyme digestion fragments to obtain a recombinant protein expression plasmid pET-28a-EmAGO2; the preparation method comprises the following steps: taking EmAGO2 as a template, transforming the EmAGO2 into competent cells, selecting positive clones for induced expression, and carrying out ultrasonication treatment, separation and purification, concentration and desalination treatment on expressed thalli to obtain the EmAGO2 truncated recombinant protein. Furthermore, a mouse anti-EmAGO2 truncated recombinant protein and goat anti-rabbit IgG are respectively used as an antigen and an antibody to establish an indirect ELISA diagnostic kit for the echinococcosis multilocularis, and the kit has high sensitivity, specificity and good repeatability, and can be used for early diagnosis of the echinococcosis multilocularis.

The invention discloses an application of ceritinib in preparation of a medicine for treating echinococcosis. The ceritinib also comprises a pharmaceutically acceptable salt or a hydrate of the salt, and a pharmaceutical composition containing pharmaceutically acceptable auxiliary materials. The invention accidentally discovers that the ceritinib has a remarkable effect of killing protoscolex in vitro. Experimental results show that when the action concentration of albendazole is 80 [mu] M, the fatality rate of albendazole to protoscolex is only 2.5% + / -0.5%, while when the action concentration of ceritinib is 10 [mu] M, the fatality rate of ceritinib to protoscolex can reach 16.00% + / -2.75%, and when the action concentration of ceritinib is 25-80 [mu] M, the fatality rate of ceritinib to protoscolex can reach 100%; microscopic experiments show that when the acting concentration of the ceritinib is 60 mu M, the protoscolex can be completely killed within 8 hours. Therefore, compared with albendazole for clinically assisting in treating the echinococcosis, the ceritinib has the advantages that the effect of killing protoscolex in vitro is more remarkable, the dosage is smaller, the safety is higher, the effect is quicker, and a new drug choice is provided for treating the echinococcosis.

The invention relates to a gene marker group, a primer, a kit and application of the gene marker group, the primer and the kit in detection of echinococcosis, and belongs to the technical field of biology. Wherein the gene marker group comprises at least one of (c1) to (c230). The gene marker group can be used for designing multiple detection primers for detecting echinococcus.

The invention discloses an echinococcus multilocularis monoclonal antibody and a fluorescent microsphere immunochromatography detection test strip, and relates to the technical field of monoclonal antibodies. The echinococcus multilocularis monoclonal antibody is an echinococcus multilocularis monoclonal antibody 13H11F4, the amino acid sequence of a heavy chain of the echinococcus multilocularis monoclonal antibody is shown as SEQ ID NO.1, and the amino acid sequence of a light chain of the echinococcus multilocularis monoclonal antibody is shown as SEQ ID NO.2. The monoclonal antibody 13H11F4 of the echinococcus multilocularis can be combined with other monoclonal antibodies of the echinococcus multilocularis, so that the echinococcus multilocularis can be detected by a double-antibody sandwich method. The fluorescent microsphere immunochromatography test strip prepared from 13H11F4 and other monoclonal antibodies of other echinococcosis multilocularis is used for medical detection of echinococcosis multilocularis, has the advantages of high sensitivity, short reaction time, strong anti-interference capability and accurate and reliable detection result, and has wide clinical application value.

The present invention provides a classification model for sheep echinococcosis and sheep brucellosis based on serum Raman spectroscopy, a method for establishing the model, and a detection device. The method for establishing the classification model for sheep echinococcosis and sheep brucellosis based on serum Raman spectroscopy comprises: (1) collecting blood from healthy sheep and diseased sheep, extracting serum, and obtaining serum samples; (2) detecting the serum samples using a laser Raman spectrometer to obtain Raman spectral data; (3) performing noise reduction, baseline correction, and normalization on the Raman spectral data to obtain pre-processed spectral data; (4) performing principal component analysis (PCA) dimensionality reduction on the processed spectral data, and then establishing a linear discriminant analysis (LDA) or support vector machine (SVM) classification model to obtain a classification model for sheep echinococcosis and sheep brucellosis. The classification model and detection device established by the present invention based on machine learning algorithms and Raman spectroscopy have potential in screening sheep infected with echinococcosis and sheep infected with brucellosis.

This invention belongs to the field of food enzyme engineering technology, specifically relating to a strain of *Aspergillus echinococcosis* that produces highly efficient ester-degrading catechin tannin enzymes and its applications. The strain is classified as *Aspergillus echinococcosis* (…). Aspergillus aculeatus LS06, with accession number CGMCC No. 42170. The *Aspergillus echinococcosis* strain provided by this invention serves as a tannin-producing strain, using inexpensive agricultural waste bran as raw material, resulting in low production costs. Simultaneously, the produced tannins exhibit high enzyme activity and high catalytic efficiency for ester-type catechins, demonstrating promising application prospects in tea beverage processing.

The invention discloses a novel anti-echinococcus monoclonal antibody, a hybridoma cell strain and application of the novel anti-echinococcus monoclonal antibody, and belongs to the technical field of biomedicine and immunology. The preservation number of the hybridoma cell strain Anti-Em-11 disclosed by the invention is CGMCC (China General Microbiological Culture Collection Center) No. 46598. According to the present invention, the specific monoclonal antibody is successfully prepared and identified, and Western blot and indirect immunofluorescence experiments prove that the obtained monoclonal antibody has high specificity on the recombinant protein. The invention lays a solid foundation for serological diagnosis of the echinococcosis and remarkably enriches the existing serological detection technical system.

This invention discloses a multilocular echinococcosis larva. In Preparation method of -6B protein and its application in the preparation of anti-host inflammatory agents. Through protein structure modeling and molecular docking technology, the preparation method was confirmed. In -6B can bind with high affinity to a key subunit of the host 26S proteasome, affecting the assembly of the proteasome in the host and thus interfering with the activity of the NF-κB signaling pathway, thereby regulating the host inflammatory response. Animal experiments have shown that recombinant... In -6B intervention significantly alleviated colonic damage in mice with inflammatory bowel disease, regulated the expression levels of pro-inflammatory and anti-inflammatory factors, and improved the survival rate of septic mice, with no obvious toxic side effects observed. This invention opens up a new pathway for developing anti-inflammatory agents using natural molecules that interact with the parasite's immune system, and provides a novel mechanism of action and biosafety for anti-host inflammatory biological agents, showing great potential for application in the prevention and treatment of inflammatory diseases in humans and livestock.

The utility model discloses a sample constant-temperature heater for detecting DNA (deoxyribonucleic acid) of hydatid in dog feces. The sample constant-temperature heater for detecting the DNA of the hydatid in the dog manure comprises a heater body, a standard module is installed on the heater body, and a quick release plate is installed at the top of the standard module in an inserted mode. According to the sample constant-temperature heater for detecting the DNA of the hydatid in the dog manure, the heater body and the standard module are arranged, the quick-release plate is inserted and mounted on the standard module, and all samples inserted on the standard module can be taken down at the same time by pulling the quick-release plate upwards, so that the time required for taking down the samples is saved, the working efficiency is improved, and the labor intensity of workers is reduced. And meanwhile, the use efficiency of the equipment is improved.

The invention discloses an application of CA170 in preparation of a medicine for treating echinococcus multilocularis, and aims to realize effective treatment on echinococcus multilocularis infection. C57 / 6J mice infected by hepatic portal veins for 40 days through alveolar coccosis serve as research objects, CA-170 micromolecules are orally administrated, the dosage of CA-170 in the medicine is not lower than 10 mg / kg, the CA-170 is treated once every three days for one month, and the drug effect of CA-170 on protoscolex cystic development and focus growth in the bodies of the echinococcus multilocularis infected mice is detected. Results show that compared with a solvent control group, in-vivo focuses of mice in a CA-170 treatment group are reduced, and the number and the weight of echinococcosis cysts are remarkably reduced, indicating that CA170 shows a good effect in the aspect of resisting echinococcosis multilocularis infection, and can reduce the proportion of MDSC caused by the infection and relieve liver injury caused by the infection. According to the application scheme provided by the invention, technical support is provided for efficiently preventing and treating the echinococcosis multilocularis, and a foundation is laid for clinical treatment of the CA-170 on the echinococcosis multilocularis.

The invention discloses an antibacterial peptide for preventing and treating echinococcosis multilocularis and application of the antibacterial peptide, and belongs to the technical field of biology. The antibacterial peptide is an antibacterial peptide C16EGGE-NH2, the structural formula of the antibacterial peptide is C16-Glu-Gly-Gly-Glu-NH2, the antibacterial peptide contains four amino acids, namely glutamic acid, glycine, glycine and glutamic acid in sequence, and the carboxyl of the last glutamic acid is amidated. Although the antibacterial peptide C16EGGE-NH2 provided by the invention has a remarkable destructive effect on protoscolex multilocularis, the toxicity to normal cells is relatively low, and the antibacterial peptide C16EGGE-NH2 has selective killing ability and shows good biological safety and potential application value.

The invention discloses an echinococcus multilocularis monoclonal antibody and a fluorescent microsphere immunochromatography detection test strip, and relates to the technical field of monoclonal antibodies. The echinococcus multilocularis monoclonal antibody is an echinococcus multilocularis monoclonal antibody 2G7C3, the amino acid sequence of a heavy chain of the echinococcus multilocularis monoclonal antibody 2G7C3 is shown as SEQ ID NO.1, and the amino acid sequence of a light chain of the echinococcus multilocularis monoclonal antibody 2G7C3 is shown as SEQ ID The echinococcosis multilocularis monoclonal antibody 2G7C3 can be combined with other monoclonal antibodies of echinococcosis multilocularis, so that the echinococcosis multilocularis can be detected by a double-antibody sandwich method. The fluorescent microsphere immunochromatography test strip prepared from 2G7C3 and other monoclonal antibodies of other echinococcosis multilocularis is used for medical detection of echinococcosis multilocularis, has the advantages of high sensitivity, short reaction time, strong anti-interference capability and accurate and reliable detection result, and has wide clinical application value.

The invention discloses an application of amlodipine in preparation of a medicine for treating echinococcosis. The amlodipine further comprises a pharmaceutically acceptable salt of the amlodipine and a pharmaceutical composition containing pharmaceutically acceptable auxiliary materials. An echinococcosis killing experiment result shows that when the highest action concentration of albendazole in an experiment is 80 [mu] M, the fatality rate of albendazole to protoscolex is only 2.5% + / -0.5%, when the action concentration of amlodipine is 20 [mu] M, the fatality rate of albendazole to protoscolex can reach 2.5% + / -0.5%, and when the action concentration of amlodipine is 60-80 [mu] M, the fatality rate of albendazole to protoscolex can reach 100%; microscopic experiments show that when the action concentration of amlodipine is 60 [mu] M, protoscolex can be killed only in 8 hours. Therefore, compared with albendazole for clinical adjuvant treatment of the echinococcosis, the amlodipine disclosed by the invention has the advantages of more obvious effect of killing protoscolex in vitro, less dosage, higher safety and quicker action, and has important reference value for developing a new drug for treating the echinococcosis.

The invention relates to the technical field of gene inhibitors, in particular to an inhibitor of a targeted macrophage UPF3B gene and application of the inhibitor in preparation of drugs for preventing or / and treating echinococcosis granulosa. In particular to siRNA capable of inhibiting the activity of macrophage UPF3B, blocking gene transcription of the macrophage or reducing the expression level of the macrophage UPF3B; the inhibitor can be used for knocking down the expression of a macrophage UPF3B gene in a macrophage model (simulating the pathophysiological process of echinococcosis granulosus) stimulated by cyst fluid of echinococcosis granulosus, regulating an AKT signal in the macrophage and inhibiting phosphorylation of AKT protein in the macrophage, so that the immune-related function of the macrophage under the stimulation of the cyst fluid is influenced, and the inhibitor can be used for preparing an anti-inflammatory drug for treating echinococcosis granulosus in a macrophage model (simulating the pathophysiological process of echinococcosis granulosus. The related pathological processes of the echinococcosis granulosa are intervened. The invention fills up the blank of developing a specific prevention and treatment preparation for echinococcosis granulosa by taking the macrophage UPF3B gene as an action target in the prior art.